Commission Implementing Decision of 13 December 2012 approving certain amended programmes for the eradication and monitoring of animal diseases and zoonoses for the year 2012 and amending Implementing Decision 2011/807/EU as regards the financial contribution by the Union for certain programmes approved by that Decision (notified under document C(2012) 9264)

The amended programme for bovine brucellosis submitted by Portugal on 30 April 2012 is hereby approved for the period from 1 January 2012 to 31 December 2012.

The amended programme for bovine tuberculosis submitted by Portugal on 30 April 2012 is hereby approved for the period from 1 January 2012 to 31 December 2012. The amended programme for bovine tuberculosis submitted by the United Kingdom on 3 August 2012 is hereby approved for the period from 1 January 2012 to 31 December 2012.

The amended programme for ovine and caprine brucellosis submitted by Spain on 30 March 2012 is hereby approved for the period from 1 January 2012 to 31 December 2012.

The amended programme for bluetongue submitted by Spain on 14 September 2012 is hereby approved for the period from 1 January 2012 to 31 December 2012. The amended programme for bluetongue submitted by Portugal on 31 December 2011 is hereby approved for the period from 1 January 2012 to 31 December 2012.

The amended programme for the control and monitoring of classical swine fever submitted by Slovenia on 19 June 2012 is hereby approved for the period from 1 January 2012 to 31 December 2012.

The amended programme for the control and monitoring of African swine fever submitted by Italy on 2 October 2012 is hereby approved for the period from 1 January 2012 to 31 December 2012.

The amended programme for the monitoring of transmissible spongiform encephalopathies, and for the eradication of bovine spongiform encephalopathy and of scrapie, submitted by Greece on 9 January 2012 is hereby approved for the period from 1 January 2012 to 31 December 2012. The amended programme for the monitoring of transmissible spongiform encephalopathies, and for the eradication of bovine spongiform encephalopathy and of scrapie, submitted by Italy on 26 September 2012 is hereby approved for the period from 1 January 2012 to 31 December 2012.

The amended programme for rabies submitted by Bulgaria on the 27 December 2011 is hereby approved for the period from 1 January 2012 to 31 December 2012.

Implementing Decision 2011/807/EU is amended as follows: (1) in Article 1(2), point (c) is replaced by the following: ‘(c) shall not exceed the following: (i) EUR 3600000 for Spain; (ii) EUR 2300000 for Italy; (iii) EUR 1050000 for Portugal; (iv) EUR 1050000 for the United Kingdom.’; (2) in Article 2(2), point (a) is replaced by the following: ‘(a) shall consist of a lump sum compensating for all costs incurred to perform the following activities and/or tests: (i) EUR 0,5 per domestic animal sampled for gamma interferon test and suspected positive in the slaughterhouse; (ii) EUR 1,5 per tuberculin test; (iii) EUR 5 per gamma interferon test; (iv) EUR 20 per bacteriological test.’; (3) in Article 2(2), point (c) is replaced by the following: ‘(c) shall not exceed the following: (i) EUR 19000000 for Ireland; (ii) EUR 14000000 for Spain; (iii) EUR 4000000 for Italy; (iv) EUR 2650000 for Portugal; (v) EUR 31000000 for the United Kingdom.’; (4) in Article 3(2), point (c) is replaced by the following: ‘(c) shall not exceed the following: (i) EUR 800000 for Greece; (ii) EUR 8900000 for Spain; (iii) EUR 3700000 for Italy; (iv) EUR 180000 for Cyprus; (v) EUR 1800000 for Portugal.’; (5) in Article 4(2), point (c) is replaced by the following: ‘(c) shall not exceed the following: (i) EUR 150000 for Belgium; (ii) EUR 15000 for Bulgaria; (iii) EUR 40000 for the Czech Republic; (iv) EUR 80000 for Germany; (v) EUR 10000 for Estonia; (vi) EUR 25000 for Ireland; (vii) EUR 60000 for Greece; (viii) EUR 700000 for Spain; (ix) EUR 1200000 for France; (x) EUR 650000 for Italy; (xi) EUR 20000 for Latvia; (xii) EUR 10000 for Lithuania; (xiii) EUR 10000 for Luxembourg; (xiv) EUR 30000 for Hungary; (xv) EUR 10000 for Malta; (xvi) EUR 20000 for the Netherlands; (xvii) EUR 10000 for Austria; (xviii) EUR 50000 for Poland; (xix) EUR 300000 for Portugal; (xx) EUR 150000 for Romania; (xxi) EUR 40000 for Slovenia; (xxii) EUR 50000 for Slovakia; (xxiii) EUR 10000 for Finland; (xxiv) EUR 10000 for Sweden.’; (6) in Article 5(3), point (c) is replaced by the following: ‘(c) shall not exceed the following: (i) EUR 1200000 for Belgium; (ii) EUR 20000 for Bulgaria; (iii) EUR 1200000 for the Czech Republic; (iv) EUR 250000 for Denmark; (v) EUR 900000 for Germany; (vi) EUR 30000 for Estonia; (vii) EUR 200000 for Ireland; (viii) EUR 1000000 for Greece; (ix) EUR 1100000 for Spain; (x) EUR 1550000 for France; (xi) EUR 1200000 for Italy; (xii) EUR 100000 for Cyprus; (xiii) EUR 350000 for Latvia; (xiv) EUR 10000 for Luxembourg; (xv) EUR 2000000 for Hungary; (xvi) EUR 150000 for Malta; (xvii) EUR 2700000 for the Netherlands; (xviii) EUR 1100000 for Austria; (xix) EUR 500000 for Poland; (xx) EUR 50000 for Portugal; (xxi) EUR 350000 for Romania; (xxii) EUR 70000 for Slovenia; (xxiii) EUR 600000 for Slovakia; (xxiv) EUR 75000 for the United Kingdom.’; (7) Article 6 is amended as follows: (a) paragraph 2 is amended as follows: (i) the introductory phrase is replaced by the following: ‘The financial contribution by the Union for the programmes submitted by the Member States referred to in point (a) of paragraph 1:’; (ii) point (b) is replaced by the following: ‘(b) shall not exceed the following: (i) EUR 210000 for Bulgaria; (ii) EUR 1200000 for Germany; (iii) EUR 200000 for France; (iv) EUR 10000 for Luxembourg; (v) EUR 340000 for Hungary; (vi) EUR 900000 for Romania; (vii) EUR 30000 for Slovenia; (viii) EUR 500000 for Slovakia.’; (b) the following paragraph 3 is added: ‘3. The financial contribution by the Union for the programme submitted by Italy as referred to in point (b) of paragraph 1: (a) shall be at the rate of 50 % of the costs to be incurred by Italy for: (i) carrying out laboratory tests with a maximum not exceeding: EUR 2 per ELISA test EUR 10 per PCR test and EUR 10 per virological test; (ii) the salaries of contractual staff specially recruited for the implementation of the measures of that programme, other than to carry out laboratory tests; (b) shall not exceed EUR 850000.’; (8) in Article 8(2), point (c) is amended as follows: (a) point (ix) is replaced by the following: ‘(ix) EUR 140000 for Spain;’; (b) point (xi) is replaced by the following: ‘(xi) EUR 1000000 for Italy;’; (c) point (xxii) is replaced by the following: ‘(xxii) EUR 350000 for Romania;’; (d) point (xxvii) is replaced by the following: ‘(xxvii) EUR 110000 for the United Kingdom.’; (9) in Article 9(2), point (c) is amended as follows: (a) point (ii) is replaced by the following: ‘(ii) EUR 340000 for Bulgaria;’; (b) point (iv) is replaced by the following: ‘(iv) EUR 750000 for Denmark;’; (c) point (v) is replaced by the following: ‘(v) EUR 6300000 for Germany;’; (d) point (viii) is replaced by the following: ‘(viii) EUR 1800000 for Greece;’; (e) point (xi) is replaced by the following: ‘(xi) EUR 4800000 for Italy;’; (f) point (xvi) is replaced by the following: ‘(xvi) EUR 1300000 for Hungary;’; (g) point (xviii) is replaced by the following: ‘(xviii) EUR 2200000 for the Netherlands;’; (h) point (xxi) is replaced by the following: ‘(xxi) EUR 1100000 for Portugal’; (i) point (xxvii) is replaced by the following: ‘(xxvii) EUR 5100000 for the United Kingdom.’; (10) in Article 10(2), point (c) is replaced by the following: ‘(c) shall not exceed the following: (i) EUR 1650000 for Bulgaria; (ii) EUR 620000 for Estonia; (iii) EUR 1400000 for Hungary; (iv) EUR 9850000 for Poland; (v) EUR 2200000 for Romania; (vi) EUR 400000 for Slovakia.’; (11) in Article 11(5), point (c) is replaced by the following: ‘(c) shall not exceed the following: (i) EUR 1200000 for Italy; (ii) EUR 1700000 for Latvia; (iii) EUR 2950000 for Lithuania; (iv) EUR 190000 for Austria; (v) EUR 840000 for Slovenia; (vi) EUR 360000 for Finland.’

This Decision is addressed to the Member States.